Biodesix (Nasdaq: BDSX), a diagnostic solutions company that specialises in lung disease, announced on Tuesday the validation and launch of a new blood draw method for Nodify Lung Nodule Risk Assessment testing. The FDA-cleared Tasso+ device facilitates capillary blood collection from a patient's upper arm, eliminating the need for venipuncture.
The Nodify Lung testing, encompassing Nodify CDT and Nodify XL2 tests, evaluates cancer risk in patients with lung nodules. Biodesix's Tasso+ device enables in-office blood collection, streamlining the Nodify Lung workflow for healthcare providers lacking access to phlebotomy services.
Biodesix obtained approval from the New York State Clinical Laboratory Evaluation Program (NYS-CLEP) for Tasso+ use, making it available for clinical specimen collection.
With a focus on lung disease diagnostics, Biodesix uses multi-omics and artificial intelligence to develop tests providing insights for clinical decisions. The company offers Medicare-covered tests and collaborates with biotechnology and pharmaceutical companies through its advanced Diagnostic Cortex AI platform to address complex diagnostic challenges in lung disease.
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy
Labcorp's PGDx elio plasma focus Dx receives US FDA De Novo marketing authorisation
Verici Dx announces completion of Thermo Fisher Scientific licensing agreement
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center